City Therapeutics Announces Pricing of Upsized Initial Public Offering

Impact · against what's priced in

City Therapeutics successfully raised approximately $200M through an upsized IPO. This provides the necessary capital to advance its RNAi pipeline, establishing a baseline valuation and liquidity for the company.

CTY+0.60

No priced-in read yet

In context

The pricing of 11,111,111 shares at $18.00 per share secures $200M in gross proceeds to fund the development of the company's RNAi pipeline.

Read from the article alone

Actual

• biotech▲5%
• ipo
• healthcare
• CTY
• clinical stage
• public offering
• rnai

Top 1 mover · tap to explore